Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial

Purpose Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulatio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Intensive care medicine Jg. 47; H. 1; S. 49 - 59
Hauptverfasser: Baksaas-Aasen, K., Gall, L. S., Stensballe, J., Juffermans, N. P., Curry, N., Maegele, M., Brooks, A., Rourke, C., Gillespie, S., Murphy, J., Maroni, R., Vulliamy, P., Henriksen, H. H., Pedersen, K. Holst, Kolstadbraaten, K. M., Wirtz, M. R., Kleinveld, D. J. B., Schäfer, N., Chinna, S., Davenport, R. A., Naess, P. A., Goslings, J. C., Eaglestone, S., Stanworth, S., Johansson, P. I., Gaarder, C., Brohi, K.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2021
Springer
Springer Nature B.V
Schlagworte:
ISSN:0342-4642, 1432-1238, 1432-1238
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Purpose Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs). Methods This was a multi-centre, randomized controlled trial comparing outcomes in trauma patients who received empiric MHPs, augmented by either VHA or CCT-guided interventions. Primary outcome was the proportion of subjects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary outcomes included 28-day mortality. Pre-specified subgroups included patients with severe traumatic brain injury (TBI). Results Of 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT-guided therapy. At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 67%, CCT: 64%, OR 1.15, 95% CI 0.76–1.73). 28-day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 95% CI 0.54–1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre-specified subgroups, there were no differences in primary outcomes. In the pre-specified subgroup of 74 patients with TBI, 64% were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84–5.34). Conclusion There was no difference in overall outcomes between VHA- and CCT-augmented-major haemorrhage protocols.
AbstractList Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs). This was a multi-centre, randomized controlled trial comparing outcomes in trauma patients who received empiric MHPs, augmented by either VHA or CCT-guided interventions. Primary outcome was the proportion of subjects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary outcomes included 28-day mortality. Pre-specified subgroups included patients with severe traumatic brain injury (TBI). Of 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT-guided therapy. At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 67%, CCT: 64%, OR 1.15, 95% CI 0.76-1.73). 28-day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 95% CI 0.54-1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre-specified subgroups, there were no differences in primary outcomes. In the pre-specified subgroup of 74 patients with TBI, 64% were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84-5.34). There was no difference in overall outcomes between VHA- and CCT-augmented-major haemorrhage protocols.
Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs).PURPOSEContemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs).This was a multi-centre, randomized controlled trial comparing outcomes in trauma patients who received empiric MHPs, augmented by either VHA or CCT-guided interventions. Primary outcome was the proportion of subjects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary outcomes included 28-day mortality. Pre-specified subgroups included patients with severe traumatic brain injury (TBI).METHODSThis was a multi-centre, randomized controlled trial comparing outcomes in trauma patients who received empiric MHPs, augmented by either VHA or CCT-guided interventions. Primary outcome was the proportion of subjects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary outcomes included 28-day mortality. Pre-specified subgroups included patients with severe traumatic brain injury (TBI).Of 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT-guided therapy. At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 67%, CCT: 64%, OR 1.15, 95% CI 0.76-1.73). 28-day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 95% CI 0.54-1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre-specified subgroups, there were no differences in primary outcomes. In the pre-specified subgroup of 74 patients with TBI, 64% were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84-5.34).RESULTSOf 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT-guided therapy. At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 67%, CCT: 64%, OR 1.15, 95% CI 0.76-1.73). 28-day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 95% CI 0.54-1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre-specified subgroups, there were no differences in primary outcomes. In the pre-specified subgroup of 74 patients with TBI, 64% were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84-5.34).There was no difference in overall outcomes between VHA- and CCT-augmented-major haemorrhage protocols.CONCLUSIONThere was no difference in overall outcomes between VHA- and CCT-augmented-major haemorrhage protocols.
Purpose Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs). Methods This was a multi-centre, randomized controlled trial comparing outcomes in trauma patients who received empiric MHPs, augmented by either VHA or CCT-guided interventions. Primary outcome was the proportion of subjects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary outcomes included 28-day mortality. Pre-specified subgroups included patients with severe traumatic brain injury (TBI). Results Of 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT-guided therapy. At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 67%, CCT: 64%, OR 1.15, 95% CI 0.76–1.73). 28-day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 95% CI 0.54–1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre-specified subgroups, there were no differences in primary outcomes. In the pre-specified subgroup of 74 patients with TBI, 64% were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84–5.34). Conclusion There was no difference in overall outcomes between VHA- and CCT-augmented-major haemorrhage protocols.
Purpose Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs). Methods This was a multi-centre, randomized controlled trial comparing outcomes in trauma patients who received empiric MHPs, augmented by either VHA or CCT-guided interventions. Primary outcome was the proportion of subjects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary outcomes included 28-day mortality. Pre-specified subgroups included patients with severe traumatic brain injury (TBI). Results Of 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT-guided therapy. At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 67%, CCT: 64%, OR 1.15, 95% CI 0.76-1.73). 28-day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 95% CI 0.54-1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre-specified subgroups, there were no differences in primary outcomes. In the pre-specified subgroup of 74 patients with TBI, 64% were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84-5.34). Conclusion There was no difference in overall outcomes between VHA- and CCT-augmented-major haemorrhage protocols.
PurposeContemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs).MethodsThis was a multi-centre, randomized controlled trial comparing outcomes in trauma patients who received empiric MHPs, augmented by either VHA or CCT-guided interventions. Primary outcome was the proportion of subjects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary outcomes included 28-day mortality. Pre-specified subgroups included patients with severe traumatic brain injury (TBI).ResultsOf 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT-guided therapy. At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 67%, CCT: 64%, OR 1.15, 95% CI 0.76–1.73). 28-day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 95% CI 0.54–1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre-specified subgroups, there were no differences in primary outcomes. In the pre-specified subgroup of 74 patients with TBI, 64% were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84–5.34).ConclusionThere was no difference in overall outcomes between VHA- and CCT-augmented-major haemorrhage protocols.
Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Haemostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs). This was a multi-centre, randomized controlled trial comparing outcomes in trauma patients who received empiric MHPs, augmented by either VHA or CCT-guided interventions. Primary outcome was the proportion of subjects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary outcomes included 28-day mortality. Pre-specified subgroups included patients with severe traumatic brain injury (TBI). Of 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT-guided therapy. At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 67%, CCT: 64%, OR 1.15, 95% CI 0.76-1.73). 28-day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 95% CI 0.54-1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre-specified subgroups, there were no differences in primary outcomes. In the pre-specified subgroup of 74 patients with TBI, 64% were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84-5.34). There was no difference in overall outcomes between VHA- and CCT-augmented-major haemorrhage protocols.
Audience Academic
Author Stensballe, J.
Maegele, M.
Davenport, R. A.
Rourke, C.
Goslings, J. C.
Maroni, R.
Wirtz, M. R.
Kolstadbraaten, K. M.
Vulliamy, P.
Gillespie, S.
Johansson, P. I.
Naess, P. A.
Gall, L. S.
Gaarder, C.
Kleinveld, D. J. B.
Chinna, S.
Curry, N.
Brohi, K.
Stanworth, S.
Brooks, A.
Baksaas-Aasen, K.
Schäfer, N.
Juffermans, N. P.
Pedersen, K. Holst
Henriksen, H. H.
Murphy, J.
Eaglestone, S.
Author_xml – sequence: 1
  givenname: K.
  surname: Baksaas-Aasen
  fullname: Baksaas-Aasen, K.
  organization: Oslo University Hospital & University of Oslo
– sequence: 2
  givenname: L. S.
  surname: Gall
  fullname: Gall, L. S.
  organization: Centre for Trauma Sciences, Queen Mary University of London, Blizard Institute
– sequence: 3
  givenname: J.
  surname: Stensballe
  fullname: Stensballe, J.
  organization: Copenhagen University Hospital, Rigshospitalet
– sequence: 4
  givenname: N. P.
  surname: Juffermans
  fullname: Juffermans, N. P.
  organization: Amsterdam University Medical Centres
– sequence: 5
  givenname: N.
  surname: Curry
  fullname: Curry, N.
  organization: Oxford University Hospital NHS Trust
– sequence: 6
  givenname: M.
  surname: Maegele
  fullname: Maegele, M.
  organization: Cologne-Merheim Medical Centre, University of Witten/Herdecke
– sequence: 7
  givenname: A.
  surname: Brooks
  fullname: Brooks, A.
  organization: Nottingham University Hospitals NHS Trust
– sequence: 8
  givenname: C.
  surname: Rourke
  fullname: Rourke, C.
  organization: Centre for Trauma Sciences, Queen Mary University of London, Blizard Institute
– sequence: 9
  givenname: S.
  surname: Gillespie
  fullname: Gillespie, S.
  organization: Centre for Trauma Sciences, Queen Mary University of London, Blizard Institute
– sequence: 10
  givenname: J.
  surname: Murphy
  fullname: Murphy, J.
  organization: Queen Mary University of London
– sequence: 11
  givenname: R.
  surname: Maroni
  fullname: Maroni, R.
  organization: Queen Mary University of London
– sequence: 12
  givenname: P.
  surname: Vulliamy
  fullname: Vulliamy, P.
  organization: Centre for Trauma Sciences, Queen Mary University of London, Blizard Institute
– sequence: 13
  givenname: H. H.
  surname: Henriksen
  fullname: Henriksen, H. H.
  organization: Copenhagen University Hospital, Rigshospitalet
– sequence: 14
  givenname: K. Holst
  surname: Pedersen
  fullname: Pedersen, K. Holst
  organization: Copenhagen University Hospital, Rigshospitalet
– sequence: 15
  givenname: K. M.
  surname: Kolstadbraaten
  fullname: Kolstadbraaten, K. M.
  organization: Oslo University Hospital & University of Oslo
– sequence: 16
  givenname: M. R.
  surname: Wirtz
  fullname: Wirtz, M. R.
  organization: Amsterdam University Medical Centres
– sequence: 17
  givenname: D. J. B.
  surname: Kleinveld
  fullname: Kleinveld, D. J. B.
  organization: Amsterdam University Medical Centres
– sequence: 18
  givenname: N.
  surname: Schäfer
  fullname: Schäfer, N.
  organization: Cologne-Merheim Medical Centre, University of Witten/Herdecke
– sequence: 19
  givenname: S.
  surname: Chinna
  fullname: Chinna, S.
  organization: Nottingham University Hospitals NHS Trust
– sequence: 20
  givenname: R. A.
  surname: Davenport
  fullname: Davenport, R. A.
  organization: Centre for Trauma Sciences, Queen Mary University of London, Blizard Institute
– sequence: 21
  givenname: P. A.
  surname: Naess
  fullname: Naess, P. A.
  organization: Oslo University Hospital & University of Oslo
– sequence: 22
  givenname: J. C.
  surname: Goslings
  fullname: Goslings, J. C.
  organization: Amsterdam University Medical Centres
– sequence: 23
  givenname: S.
  surname: Eaglestone
  fullname: Eaglestone, S.
  organization: Centre for Trauma Sciences, Queen Mary University of London, Blizard Institute
– sequence: 24
  givenname: S.
  surname: Stanworth
  fullname: Stanworth, S.
  organization: Oxford University Hospital NHS Trust, NHS Blood and Transplant
– sequence: 25
  givenname: P. I.
  surname: Johansson
  fullname: Johansson, P. I.
  organization: Copenhagen University Hospital, Rigshospitalet
– sequence: 26
  givenname: C.
  surname: Gaarder
  fullname: Gaarder, C.
  organization: Oslo University Hospital & University of Oslo
– sequence: 27
  givenname: K.
  surname: Brohi
  fullname: Brohi, K.
  email: k.brohi@qmul.ac.uk
  organization: Centre for Trauma Sciences, Queen Mary University of London, Blizard Institute
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33048195$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1r2zAYhcXoWNNuf2AXw7CbFuZOsiVb7sUghH0ECrvJdiveyK8dBdnKJHuQ_frJTbuuJRSBJeznHFlH54yc9K5HQt4yesUoLT8GSlnOU5rRlBZZUaTsBZkxnmcpy3J5QmY051nKC56dkrMQthEvC8FekdM8p1yySszI_qcJ2qGFMBidbAA7FwaY1hAC7BMY2w77Aetk593gtLMhaZxPOtjG5-Bh7OAg834DLSYXy9V8sVouLq8TSDz0tevMH6w_JNr1g3fWRqvBG7CvycsGbMA3d_M5-fHl82rxLb35_nW5mN-kWpTVkDKGFa_KhnKgrJDrotIFSsEoR1zzRq-btSzigEbLUmNZQFU1yDXUkgqu8_ycfDr47sZ1h7WOp_Fg1c6bDvxeOTDq8ZfebFTrfqtSCCr5ZHBxZ-DdrxHDoLqYGVoLPboxqIwLWpQxUhHR90_QrRt9H48XqVLQmLqoHqgWLCrTNy7uqydTNS-zvGJ5KWWk0iNUiz3Gn4xFaEx8_Yi_OsLHUWNn9FHBu_-D-ZfIfTkiIA-A9i4Ej43SZurGdJFgrGJUTT1Uhx6q2EN120PFojR7Ir13f1aUH0Qhwn2L_iG9Z1R_AeW4700
CitedBy_id crossref_primary_10_1111_aas_14558
crossref_primary_10_1016_j_injury_2021_10_034
crossref_primary_10_1111_trf_17808
crossref_primary_10_1111_vox_13732
crossref_primary_10_1109_TBCAS_2023_3291875
crossref_primary_10_1136_archdischild_2024_327224
crossref_primary_10_1007_s00134_023_06980_6
crossref_primary_10_1097_TA_0000000000004463
crossref_primary_10_1097_ALN_0000000000004268
crossref_primary_10_1186_s13741_025_00562_4
crossref_primary_10_1016_j_injury_2023_111124
crossref_primary_10_1097_CCE_0000000000000526
crossref_primary_10_1097_MCC_0000000000000992
crossref_primary_10_1007_s00068_021_01788_9
crossref_primary_10_1186_s13613_025_01447_x
crossref_primary_10_1080_00325481_2024_2320080
crossref_primary_10_1177_00031348241309563
crossref_primary_10_1213_ANE_0000000000005765
crossref_primary_10_1111_bjh_18246
crossref_primary_10_1213_ANE_0000000000006174
crossref_primary_10_1001_jamanetworkopen_2025_32702
crossref_primary_10_1111_trf_16944
crossref_primary_10_1186_s13054_023_04688_z
crossref_primary_10_1007_s00068_025_02919_2
crossref_primary_10_3390_jcm13123612
crossref_primary_10_1016_j_jtha_2023_04_008
crossref_primary_10_1016_S1773_035X_24_00262_4
crossref_primary_10_1016_j_suc_2023_09_005
crossref_primary_10_1111_1742_6723_13767
crossref_primary_10_1186_s13063_022_06739_2
crossref_primary_10_1001_jama_2023_21019
crossref_primary_10_1016_j_redare_2023_05_003
crossref_primary_10_1016_j_wneu_2021_01_107
crossref_primary_10_1016_j_jtha_2023_12_002
crossref_primary_10_1016_j_rpth_2023_100163
crossref_primary_10_1515_cclm_2025_0775
crossref_primary_10_3390_ijms25147763
crossref_primary_10_1016_j_medin_2023_03_007
crossref_primary_10_1177_00031348211033542
crossref_primary_10_1097_MCC_0000000000001267
crossref_primary_10_1016_j_medin_2023_03_003
crossref_primary_10_1111_aas_14568
crossref_primary_10_1055_s_0042_1757545
crossref_primary_10_3390_jcm14155426
crossref_primary_10_4037_ccn2023371
crossref_primary_10_1007_s00134_020_06301_1
crossref_primary_10_3390_jcm13133669
crossref_primary_10_1016_j_jfma_2025_07_016
crossref_primary_10_1097_TA_0000000000003960
crossref_primary_10_1097_MCC_0000000000001027
crossref_primary_10_1016_j_wneu_2021_10_180
crossref_primary_10_1097_ACO_0000000000001093
crossref_primary_10_1177_0310057X211060845
crossref_primary_10_1002_ajh_26285
crossref_primary_10_1007_s00134_023_07303_5
crossref_primary_10_1111_ijlh_14144
crossref_primary_10_1097_TA_0000000000003333
crossref_primary_10_1016_j_acci_2024_11_003
crossref_primary_10_7759_cureus_83839
crossref_primary_10_1097_MOH_0000000000000843
crossref_primary_10_1111_trf_18414
crossref_primary_10_3390_diagnostics14070708
crossref_primary_10_3389_fpubh_2023_1309094
crossref_primary_10_1097_ACO_0000000000001025
crossref_primary_10_1007_s00068_022_01882_6
crossref_primary_10_1186_s13054_023_04637_w
crossref_primary_10_1016_j_emc_2022_09_010
crossref_primary_10_1097_CCE_0000000000001097
crossref_primary_10_1080_00365513_2022_2119599
crossref_primary_10_1016_j_cpha_2025_06_005
crossref_primary_10_1111_jvim_17050
crossref_primary_10_1097_CCM_0000000000005700
crossref_primary_10_1007_s12028_024_02051_w
crossref_primary_10_1016_j_bjae_2024_08_005
crossref_primary_10_1053_j_jvca_2023_08_133
crossref_primary_10_1007_s00068_025_02808_8
crossref_primary_10_1016_j_bjae_2024_09_005
crossref_primary_10_1097_GRF_0000000000000921
crossref_primary_10_1111_trf_16455
crossref_primary_10_3389_fped_2025_1459455
crossref_primary_10_1136_emermed_2024_214054
crossref_primary_10_1182_blood_2023022901
crossref_primary_10_3390_jcm10215039
crossref_primary_10_5005_jp_journals_10030_1498
crossref_primary_10_3389_fimmu_2022_991048
crossref_primary_10_1111_vox_13206
crossref_primary_10_1016_j_acepjo_2024_100042
crossref_primary_10_1097_TA_0000000000003802
crossref_primary_10_1080_00365513_2022_2040048
crossref_primary_10_1186_s13049_025_01388_1
crossref_primary_10_1002_14651858_CD012635_pub2
crossref_primary_10_1016_j_redare_2023_08_001
crossref_primary_10_1186_s13054_023_04421_w
crossref_primary_10_1016_j_medine_2023_03_017
crossref_primary_10_1007_s00134_021_06396_0
crossref_primary_10_1016_j_medine_2023_03_019
crossref_primary_10_1016_j_accpm_2024_101366
crossref_primary_10_1016_j_accpm_2025_101543
crossref_primary_10_1016_j_nec_2025_03_006
crossref_primary_10_1093_neuros_nyab358
crossref_primary_10_1016_j_accpm_2024_101360
crossref_primary_10_1080_17474086_2021_1858788
crossref_primary_10_1186_s13054_022_04243_2
crossref_primary_10_1186_s13054_023_04537_z
crossref_primary_10_36290_aim_2023_050
crossref_primary_10_1016_j_bjae_2021_05_005
crossref_primary_10_1016_j_rpth_2022_100022
crossref_primary_10_1097_ACO_0000000000001465
crossref_primary_10_1007_s00068_021_01652_w
crossref_primary_10_5492_wjccm_v14_i2_102521
crossref_primary_10_1007_s43678_025_00929_y
crossref_primary_10_1016_j_wneu_2022_06_079
crossref_primary_10_1007_s12028_022_01647_4
crossref_primary_10_1097_ACO_0000000000001467
crossref_primary_10_1097_PCC_0000000000002855
crossref_primary_10_1111_tme_13109
crossref_primary_10_1159_000519696
crossref_primary_10_1001_jama_2023_4080
crossref_primary_10_1097_AIA_0000000000000318
crossref_primary_10_1161_ATVBAHA_123_318801
crossref_primary_10_1007_s00134_022_06834_7
crossref_primary_10_3390_diagnostics15091148
crossref_primary_10_1097_ALN_0000000000005189
crossref_primary_10_1097_ALN_0000000000004655
crossref_primary_10_1111_tme_70003
crossref_primary_10_1016_j_tmrv_2021_06_005
crossref_primary_10_1097_TA_0000000000004526
crossref_primary_10_1016_j_medin_2021_04_006
crossref_primary_10_1097_ALN_0000000000005183
crossref_primary_10_1097_TA_0000000000004088
crossref_primary_10_1016_j_pratan_2025_06_007
crossref_primary_10_1016_j_rpth_2024_102663
crossref_primary_10_1016_j_tmrv_2021_06_008
crossref_primary_10_1097_ALN_0000000000004520
crossref_primary_10_1111_anae_15866
crossref_primary_10_1111_tme_13018
crossref_primary_10_1007_s40140_024_00637_w
crossref_primary_10_1186_s13054_024_04805_6
crossref_primary_10_1038_s41572_021_00264_3
crossref_primary_10_1097_TA_0000000000003323
crossref_primary_10_3390_jcm11010018
crossref_primary_10_1016_j_rpth_2022_100031
crossref_primary_10_1002_jac5_1829
crossref_primary_10_1097_TA_0000000000004098
crossref_primary_10_1136_emermed_2021_211189
crossref_primary_10_3390_encyclopedia5030110
crossref_primary_10_1097_ALN_0000000000004750
crossref_primary_10_1016_j_medine_2022_02_004
crossref_primary_10_1111_1742_6723_14356
crossref_primary_10_4103_JOAPM_JOAPM_1_25
crossref_primary_10_1111_tme_13128
crossref_primary_10_1213_ANE_0000000000005709
crossref_primary_10_36290_aim_2020_058
crossref_primary_10_1016_j_bja_2024_10_047
crossref_primary_10_1136_tsaco_2023_001160
crossref_primary_10_1016_j_anrea_2025_04_006
crossref_primary_10_1186_s13054_023_04327_7
crossref_primary_10_1186_s13054_024_04955_7
crossref_primary_10_1111_1742_6723_70131
crossref_primary_10_1097_TA_0000000000004385
crossref_primary_10_1111_anae_15608
crossref_primary_10_3390_medicina59010047
crossref_primary_10_1177_17511437231206013
crossref_primary_10_1182_blood_2022016558
crossref_primary_10_1016_j_mporth_2021_02_001
crossref_primary_10_1111_1742_6723_13734
crossref_primary_10_1097_TA_0000000000003624
crossref_primary_10_1016_j_tmrv_2021_08_006
crossref_primary_10_1213_ANE_0000000000006099
crossref_primary_10_1111_vox_13382
crossref_primary_10_1016_j_injury_2024_112021
crossref_primary_10_3390_jcm11020356
crossref_primary_10_1186_s13017_022_00454_8
crossref_primary_10_1007_s10049_023_01147_8
crossref_primary_10_1097_AS9_0000000000000167
crossref_primary_10_1007_s00113_023_01300_5
crossref_primary_10_1007_s40140_022_00532_2
crossref_primary_10_1111_bjh_18275
crossref_primary_10_1016_j_accpm_2022_101180
crossref_primary_10_3390_jcm12082809
crossref_primary_10_1016_j_mpaic_2021_10_022
crossref_primary_10_1097_TA_0000000000004170
crossref_primary_10_1111_trf_16971
crossref_primary_10_1016_j_mpaic_2024_09_011
crossref_primary_10_1007_s00134_024_07437_0
crossref_primary_10_1093_ajhp_zxaf164
crossref_primary_10_1016_j_jtha_2022_11_005
crossref_primary_10_5005_jp_journals_10030_1413
crossref_primary_10_1111_acem_14393
crossref_primary_10_1007_s00101_025_01524_7
crossref_primary_10_1007_s00134_023_07089_6
crossref_primary_10_1111_trf_18349
crossref_primary_10_1097_MCC_0000000000001107
crossref_primary_10_1097_PCC_0000000000003414
crossref_primary_10_1016_j_redar_2023_05_003
crossref_primary_10_1007_s12028_022_01535_x
crossref_primary_10_1016_j_redar_2023_05_001
crossref_primary_10_1097_JTN_0000000000000722
crossref_primary_10_1055_a_2215_8936
crossref_primary_10_1055_s_0042_1756305
crossref_primary_10_1097_ALN_0000000000004711
Cites_doi 10.1111/trf.12214
10.1213/ANE.0000000000001516
10.1186/s13054-014-0518-9
10.1186/s13049-016-0308-2
10.1016/S0140-6736(19)32233-0
10.1007/s00134-019-05900-x
10.1007/s00134-017-4895-9
10.1097/TA.0000000000001270
10.1097/SLA.0b013e3182658180
10.1097/TA.0b013e31827e20e0
10.1016/S0140-6736(12)61224-0
10.1097/CCM.0b013e3182281af5
10.1002/bjs.10330
10.1186/s13054-015-0823-y
10.1016/S1474-4422(19)30232-7
10.1007/s00134-019-05560-x
10.1097/00005373-198909000-00002
10.1111/j.1538-7836.2010.03945.x
10.1007/s00134-019-05805-9
10.1016/S1474-4422(17)30197-7
10.1186/s13063-017-2224-9
10.1097/SLA.0000000000002825
10.1007/s00134-014-3584-1
10.1186/cc8948
10.1097/SLA.0000000000001608
10.1016/S0140-6736(11)60278-X
10.1097/SLA.0000000000003657
10.1002/14651858.CD007871.pub2
10.1002/14651858.CD010438.pub2
ContentType Journal Article
Copyright The Author(s) 2020
COPYRIGHT 2021 Springer
The Author(s) 2020. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2020
– notice: COPYRIGHT 2021 Springer
– notice: The Author(s) 2020. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7X7
7XB
88E
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FR3
FYUFA
GHDGH
K9.
M0S
M1P
M7Z
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1007/s00134-020-06266-1
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Biochemistry Abstracts 1
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Biochemistry Abstracts 1
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic


Technology Research Database


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7RV
  name: ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25.
  url: https://search.proquest.com/nahs
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-1238
EndPage 59
ExternalDocumentID PMC7550843
A723913788
33048195
10_1007_s00134_020_06266_1
Genre Randomized Controlled Trial
Journal Article
GeographicLocations United States
United Kingdom
GeographicLocations_xml – name: United Kingdom
– name: United States
GrantInformation_xml – fundername: Seventh Framework Programme
  grantid: F3-2013-602771
  funderid: http://dx.doi.org/10.13039/100011102
– fundername: Seventh Framework Programme
  grantid: F3-2013-602771
– fundername: ;
  grantid: F3-2013-602771
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.55
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1N0
1SB
2.D
203
28-
29J
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
78A
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AAQQT
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHFT
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABOCM
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFO
ACGFS
ACHSB
ACHVE
ACHXU
ACIHN
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEAQA
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFFNX
AFJLC
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKEYQ
BPHCQ
BSONS
BVXVI
C6C
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IAO
IEA
IHE
IHR
IJ-
IKXTQ
IMOTQ
INH
IOF
ITC
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
J5H
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
LMP
M1P
M4Y
MA-
MJL
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
WOW
X7M
YCJ
YLTOR
Z45
Z5O
Z7U
Z7X
Z82
Z83
Z86
Z87
Z8O
Z8V
Z8W
Z8Z
Z91
ZGI
ZMTXR
ZOVNA
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
ADHKG
AEZWR
AFDZB
AFFHD
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FD
8FK
FR3
K9.
M7Z
P64
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c579t-11e9497f04a0168b69c6e85104eeb4fcbfb86868afc87ce76a99fe4cad8054c33
IEDL.DBID BENPR
ISICitedReferencesCount 208
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000578323800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0342-4642
1432-1238
IngestDate Tue Nov 04 01:59:46 EST 2025
Fri Sep 05 07:22:10 EDT 2025
Wed Nov 05 07:49:20 EST 2025
Sat Nov 29 13:22:57 EST 2025
Sat Nov 29 11:18:34 EST 2025
Sat Nov 29 10:02:13 EST 2025
Wed Feb 19 02:24:56 EST 2025
Sat Nov 29 05:59:46 EST 2025
Tue Nov 18 21:51:09 EST 2025
Fri Feb 21 02:48:19 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Thromboelastometry
Thrombelastography
Haemorrhage
Trauma
Coagulopathy
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c579t-11e9497f04a0168b69c6e85104eeb4fcbfb86868afc87ce76a99fe4cad8054c33
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://link.springer.com/10.1007/s00134-020-06266-1
PMID 33048195
PQID 2475004859
PQPubID 48752
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7550843
proquest_miscellaneous_2450673305
proquest_journals_2475004859
gale_infotracmisc_A723913788
gale_infotracgeneralonefile_A723913788
gale_infotracacademiconefile_A723913788
pubmed_primary_33048195
crossref_citationtrail_10_1007_s00134_020_06266_1
crossref_primary_10_1007_s00134_020_06266_1
springer_journals_10_1007_s00134_020_06266_1
PublicationCentury 2000
PublicationDate 2021-01-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: United States
– name: Heidelberg
PublicationTitle Intensive care medicine
PublicationTitleAbbrev Intensive Care Med
PublicationTitleAlternate Intensive Care Med
PublicationYear 2021
Publisher Springer Berlin Heidelberg
Springer
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer
– name: Springer Nature B.V
References Winearls, Reade, Miles (CR20) 2016; 123
Holcomb, Minei, Scerbo (CR12) 2012; 256
Steyerberg, Wiegers, Sewalt (CR29) 2019; 18
CR18
Frith, Gosling, Gaarder (CR24) 2010; 8
Holcomb, Tilley, Baraniuk (CR6) 2015; 313
Asehnoune, Balogh, Citerio (CR32) 2017; 43
CR16
Gennarelli, Champion, Sacco, Copes, Alves (CR23) 1989; 29
Davenport, Manson, DeʼAth (CR9) 2011; 39
Veigas, Callum, Rizoli, Nascimento, da Luz (CR19) 2016; 24
Tapia, Chang, Norman (CR14) 2013; 74
Einersen, Moore, Chapman (CR15) 2017; 82
Johansson, Sørensen, Larsen (CR10) 2013; 53
Gruen, Brohi, Schreiber (CR1) 2012; 380
Brohi, Gruen, Holcomb (CR3) 2019; 45
CR2
Baksaas-Aasen, Gall, Eaglestone (CR22) 2017; 18
Hawryluk, Aguilera, Buki (CR30) 2019; 45
CR5
Khan, Davenport, Raza (CR7) 2015; 41
CR28
Schochl, Nienaber, Hofer (CR13) 2010; 14
Maegele, Schöchl, Menovsky (CR26) 2017; 16
Chesnut, Aguilera, Buki (CR31) 2020; 46
Da Luz, Nascimento, Shankarakutty, Rizoli, Adhikari (CR17) 2014; 18
Hagemo, Christiaans, Stanworth (CR11) 2015; 19
(CR4) 2011; 377
Gonzalez, Moore, Moore (CR25) 2016; 263
Balvers, van Dieren, Baksaas-Aasen (CR8) 2017; 104
Baksaas-Aasen, van Dieren, Balvers (CR21) 2019; 270
(CR27) 2019; 394
E Gonzalez (6266_CR25) 2016; 263
6266_CR18
R Davenport (6266_CR9) 2011; 39
H Schochl (6266_CR13) 2010; 14
K Baksaas-Aasen (6266_CR21) 2019; 270
K Baksaas-Aasen (6266_CR22) 2017; 18
K Brohi (6266_CR3) 2019; 45
JB Holcomb (6266_CR6) 2015; 313
D Frith (6266_CR24) 2010; 8
6266_CR16
The CRASH-3 trial collaborators (6266_CR27) 2019; 394
TA Gennarelli (6266_CR23) 1989; 29
RL Gruen (6266_CR1) 2012; 380
M Maegele (6266_CR26) 2017; 16
J Winearls (6266_CR20) 2016; 123
6266_CR2
6266_CR5
6266_CR28
GWJ Hawryluk (6266_CR30) 2019; 45
S Khan (6266_CR7) 2015; 41
PI Johansson (6266_CR10) 2013; 53
PV Veigas (6266_CR19) 2016; 24
PM Einersen (6266_CR15) 2017; 82
R Chesnut (6266_CR31) 2020; 46
EW Steyerberg (6266_CR29) 2019; 18
NM Tapia (6266_CR14) 2013; 74
K Asehnoune (6266_CR32) 2017; 43
CRASH-2 collaborators (6266_CR4) 2011; 377
K Balvers (6266_CR8) 2017; 104
LT Da Luz (6266_CR17) 2014; 18
JB Holcomb (6266_CR12) 2012; 256
JS Hagemo (6266_CR11) 2015; 19
33123786 - Intensive Care Med. 2021 Jan;47(1):80-82
35925321 - Intensive Care Med. 2022 Nov;48(11):1642-1645
33860340 - Intensive Care Med. 2021 Jun;47(6):726-727
References_xml – volume: 53
  start-page: 3088
  year: 2013
  end-page: 3099
  ident: CR10
  article-title: Low haemorrhage-related mortality in trauma patients in a Level I trauma centre employing transfusion packages and early thromboelastography-directed haemostatic resuscitation with plasma and platelets
  publication-title: Transfusion
  doi: 10.1111/trf.12214
– volume: 123
  start-page: 910
  year: 2016
  end-page: 924
  ident: CR20
  article-title: Targeted coagulation management in severe trauma: the controversies and the evidence
  publication-title: Anesth Analg
  doi: 10.1213/ANE.0000000000001516
– ident: CR18
– volume: 18
  start-page: 518
  year: 2014
  ident: CR17
  article-title: Effect of thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: descriptive systematic review
  publication-title: Crit Care
  doi: 10.1186/s13054-014-0518-9
– volume: 24
  start-page: 114
  year: 2016
  ident: CR19
  article-title: A systematic review on the rotational thrombelastometry (ROTEM®) values for the diagnosis of coagulopathy, prediction and guidance of blood transfusion and prediction of mortality in trauma patients
  publication-title: Scand J Trauma, Resusc Emerg Med
  doi: 10.1186/s13049-016-0308-2
– volume: 394
  start-page: 1713
  year: 2019
  end-page: 1723
  ident: CR27
  article-title: Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)32233-0
– volume: 46
  start-page: 919
  year: 2020
  end-page: 929
  ident: CR31
  article-title: A management algorithm for adult patients with both brain oxygen and intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC)
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-019-05900-x
– volume: 43
  start-page: 1340
  year: 2017
  end-page: 1351
  ident: CR32
  article-title: The research agenda for trauma critical care
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-017-4895-9
– volume: 82
  start-page: 114
  year: 2017
  end-page: 119
  ident: CR15
  article-title: Rapid-thrombelastography (r-TEG) thresholds for goal-directed resuscitation of patients at risk for massive transfusion
  publication-title: J Trauma Acute Care Surg
  doi: 10.1097/TA.0000000000001270
– ident: CR2
– ident: CR16
– volume: 256
  start-page: 476
  year: 2012
  end-page: 486
  ident: CR12
  article-title: Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department
  publication-title: Ann Surg
  doi: 10.1097/SLA.0b013e3182658180
– volume: 74
  start-page: 378
  year: 2013
  end-page: 385
  ident: CR14
  article-title: TEG-guided resuscitation is superior to standardized MTP resuscitation in massively transfused penetrating trauma patients
  publication-title: J Trauma Acute Care Surg
  doi: 10.1097/TA.0b013e31827e20e0
– volume: 380
  start-page: 1099
  year: 2012
  end-page: 1108
  ident: CR1
  article-title: Haemorrhage control in severely injured patients
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)61224-0
– volume: 39
  start-page: 2652
  year: 2011
  end-page: 2658
  ident: CR9
  article-title: Functional definition and characterization of acute traumatic coagulopathy
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0b013e3182281af5
– volume: 104
  start-page: 222
  year: 2017
  end-page: 229
  ident: CR8
  article-title: Combined effect of therapeutic strategies for bleeding injury on early survival, transfusion needs and correction of coagulopathy
  publication-title: Br J Surg
  doi: 10.1002/bjs.10330
– volume: 19
  start-page: 97
  year: 2015
  ident: CR11
  article-title: Detection of acute traumatic coagulopathy and massive transfusion requirements by means of rotational thromboelastometry: an international prospective validation study
  publication-title: Crit Care
  doi: 10.1186/s13054-015-0823-y
– volume: 18
  start-page: 923
  year: 2019
  end-page: 934
  ident: CR29
  article-title: Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(19)30232-7
– volume: 45
  start-page: 709
  year: 2019
  end-page: 711
  ident: CR3
  article-title: Why are bleeding trauma patients still dying?
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-019-05560-x
– volume: 29
  start-page: 1193
  year: 1989
  end-page: 1201
  ident: CR23
  article-title: Mortality of patients with head injury and extracranial injury treated in trauma centres
  publication-title: J Trauma
  doi: 10.1097/00005373-198909000-00002
– volume: 8
  start-page: 1919
  year: 2010
  end-page: 1925
  ident: CR24
  article-title: Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2010.03945.x
– volume: 45
  start-page: 1783
  year: 2019
  end-page: 1794
  ident: CR30
  article-title: A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC)
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-019-05805-9
– volume: 16
  start-page: 630
  year: 2017
  end-page: 647
  ident: CR26
  article-title: Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(17)30197-7
– volume: 313
  start-page: 471
  year: 2015
  end-page: 482
  ident: CR6
  article-title: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma
  publication-title: PROPPR Rand Clin Trial JAMA
– volume: 18
  start-page: 486
  year: 2017
  ident: CR22
  article-title: iTACTIC—implementing treatment algorithms for the correction of trauma—induced coagulopathy: study protocol for a multicentre, randomised controlled trial
  publication-title: Trials
  doi: 10.1186/s13063-017-2224-9
– ident: CR5
– volume: 270
  start-page: 1178
  year: 2019
  end-page: 1185
  ident: CR21
  article-title: Data-driven development of ROTEM and TEG algorithms for the management of trauma hemorrhage
  publication-title: Ann Surg
  doi: 10.1097/SLA.0000000000002825
– volume: 41
  start-page: 239
  year: 2015
  end-page: 247
  ident: CR7
  article-title: Damage control resuscitation using blood component therapy in standard doses has a limited effect on coagulopathy during trauma haemorrhage
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-014-3584-1
– ident: CR28
– volume: 14
  start-page: R55
  year: 2010
  ident: CR13
  article-title: Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate
  publication-title: Crit Care
  doi: 10.1186/cc8948
– volume: 263
  start-page: 1051
  year: 2016
  end-page: 1059
  ident: CR25
  article-title: Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays
  publication-title: Ann Surg
  doi: 10.1097/SLA.0000000000001608
– volume: 377
  start-page: 1096
  year: 2011
  end-page: 1101
  ident: CR4
  article-title: The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60278-X
– volume: 39
  start-page: 2652
  year: 2011
  ident: 6266_CR9
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0b013e3182281af5
– volume: 263
  start-page: 1051
  year: 2016
  ident: 6266_CR25
  publication-title: Ann Surg
  doi: 10.1097/SLA.0000000000001608
– volume: 41
  start-page: 239
  year: 2015
  ident: 6266_CR7
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-014-3584-1
– volume: 45
  start-page: 1783
  year: 2019
  ident: 6266_CR30
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-019-05805-9
– ident: 6266_CR5
– volume: 377
  start-page: 1096
  year: 2011
  ident: 6266_CR4
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60278-X
– volume: 256
  start-page: 476
  year: 2012
  ident: 6266_CR12
  publication-title: Ann Surg
  doi: 10.1097/SLA.0b013e3182658180
– volume: 74
  start-page: 378
  year: 2013
  ident: 6266_CR14
  publication-title: J Trauma Acute Care Surg
  doi: 10.1097/TA.0b013e31827e20e0
– volume: 46
  start-page: 919
  year: 2020
  ident: 6266_CR31
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-019-05900-x
– volume: 82
  start-page: 114
  year: 2017
  ident: 6266_CR15
  publication-title: J Trauma Acute Care Surg
  doi: 10.1097/TA.0000000000001270
– volume: 53
  start-page: 3088
  year: 2013
  ident: 6266_CR10
  publication-title: Transfusion
  doi: 10.1111/trf.12214
– ident: 6266_CR2
  doi: 10.1097/SLA.0000000000003657
– volume: 270
  start-page: 1178
  year: 2019
  ident: 6266_CR21
  publication-title: Ann Surg
  doi: 10.1097/SLA.0000000000002825
– volume: 18
  start-page: 923
  year: 2019
  ident: 6266_CR29
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(19)30232-7
– volume: 18
  start-page: 518
  year: 2014
  ident: 6266_CR17
  publication-title: Crit Care
  doi: 10.1186/s13054-014-0518-9
– volume: 18
  start-page: 486
  year: 2017
  ident: 6266_CR22
  publication-title: Trials
  doi: 10.1186/s13063-017-2224-9
– volume: 104
  start-page: 222
  year: 2017
  ident: 6266_CR8
  publication-title: Br J Surg
  doi: 10.1002/bjs.10330
– volume: 19
  start-page: 97
  year: 2015
  ident: 6266_CR11
  publication-title: Crit Care
  doi: 10.1186/s13054-015-0823-y
– volume: 24
  start-page: 114
  year: 2016
  ident: 6266_CR19
  publication-title: Scand J Trauma, Resusc Emerg Med
  doi: 10.1186/s13049-016-0308-2
– volume: 45
  start-page: 709
  year: 2019
  ident: 6266_CR3
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-019-05560-x
– volume: 313
  start-page: 471
  year: 2015
  ident: 6266_CR6
  publication-title: PROPPR Rand Clin Trial JAMA
– volume: 123
  start-page: 910
  year: 2016
  ident: 6266_CR20
  publication-title: Anesth Analg
  doi: 10.1213/ANE.0000000000001516
– ident: 6266_CR28
– volume: 43
  start-page: 1340
  year: 2017
  ident: 6266_CR32
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-017-4895-9
– ident: 6266_CR16
  doi: 10.1002/14651858.CD007871.pub2
– volume: 16
  start-page: 630
  year: 2017
  ident: 6266_CR26
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(17)30197-7
– volume: 29
  start-page: 1193
  year: 1989
  ident: 6266_CR23
  publication-title: J Trauma
  doi: 10.1097/00005373-198909000-00002
– volume: 394
  start-page: 1713
  year: 2019
  ident: 6266_CR27
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)32233-0
– volume: 14
  start-page: R55
  year: 2010
  ident: 6266_CR13
  publication-title: Crit Care
  doi: 10.1186/cc8948
– ident: 6266_CR18
  doi: 10.1002/14651858.CD010438.pub2
– volume: 8
  start-page: 1919
  year: 2010
  ident: 6266_CR24
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2010.03945.x
– volume: 380
  start-page: 1099
  year: 2012
  ident: 6266_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)61224-0
– reference: 33860340 - Intensive Care Med. 2021 Jun;47(6):726-727
– reference: 33123786 - Intensive Care Med. 2021 Jan;47(1):80-82
– reference: 35925321 - Intensive Care Med. 2022 Nov;48(11):1642-1645
SSID ssj0017651
Score 2.6761816
Snippet Purpose Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We...
Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We aimed to...
Purpose Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We...
PurposeContemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols (MHPs) to prevent and treat coagulopathy. We...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 49
SubjectTerms Anesthesiology
Bleeding
Blood
Blood Coagulation Disorders
Brain
Coagulation
Comparative analysis
Critical Care Medicine
Emergency Medicine
Head injuries
Hemorrhage
Hemorrhage - etiology
Hemorrhage - therapy
Hemostasis
Hemostatics
Humans
Injuries
Intensive
Intensive care
Medical equipment and supplies industry
Medical examination
Medical test kit industry
Medicine
Medicine & Public Health
Mortality
Multicenter Studies as Topic
Original
Pain Medicine
Pediatrics
Pneumology/Respiratory System
Resuscitation
Subgroups
Thrombelastography
Tranexamic acid
Transfusion
Trauma
Traumatic brain injury
United Kingdom
United States
Viscoelasticity
Wounds and Injuries - complications
Wounds and Injuries - therapy
SummonAdditionalLinks – databaseName: SpringerLink
  dbid: RSV
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9QwEB_kFPHL-faqp0QQH3iFPtI8_HYcHvrBQ_Q87ltJ0_R25baV7a5w_vXOpA_tcgpKYSmbSUjTycwvzeQ3AM9cFJWWZpqrrAl5XNmwyHQSikpJpQWlOI58sgl5dKROT_XH_lBYO0S7D1uS3lKPh90IrfCQljsRonAR4prnKro7RdPx0-eTce9ACp90kbjtQo7wuj8qc3kbE3e0aZR_80qbEZMb26beGx3e_L_nuAXbPfpk-5263IYrrr4D1z_0--t34eJk3trGIaJGATYzbtHQiSO8R4xtLphZn3kSz5IRv0ODStQyRL1sYb7iL_Z5vTBdteVyhpaKvXx_TGEqB6_eMMPQLZbNYv7DlXusD5E_x6Z84pB78OXw7fHBu7BPzhDaTOpVGMdOcy2riBtEjaoQ2gqH8C3izhW8skVVKIGXqayS1klhtK4ct6ZUiBJtmt6Hrbqp3Q6wUqjI4P-isjG2VqjUJFFSoimJ49TKLIB4eEe57ZnLKYHGeT5yLvsxzXFMcz-meRzA67HOt46346_SL-jV5zSpsWVr-rMJ2D-ix8r3ZZLqmKj3A3g-kTzryMEvE9ydCOKstdPiQcvy3mq0ecIRv6FJzXQAT8diqkmRcLVr1iSTUW4hNNMBPOiUcnxA-jZF-6IByIm6jgLEJT4tqeczzykucaWqeBrA3qC0v7r153F7-G_ij-BGQiFB_gvWLmytlmv3GK7Z76t5u3ziZ_FPomhAiA
  priority: 102
  providerName: Springer Nature
Title Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial
URI https://link.springer.com/article/10.1007/s00134-020-06266-1
https://www.ncbi.nlm.nih.gov/pubmed/33048195
https://www.proquest.com/docview/2475004859
https://www.proquest.com/docview/2450673305
https://pubmed.ncbi.nlm.nih.gov/PMC7550843
Volume 47
WOSCitedRecordID wos000578323800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAVX
  databaseName: Springer Journals
  customDbUrl:
  eissn: 1432-1238
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017651
  issn: 0342-4642
  databaseCode: RSV
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3rb9MwED-xDiG-8H4ExmQkxEMsIg83tvmCxrQJPlBNZVT9FjmOsxatzegDafz13LluRirYF1TJauqzZdfnu4vv_DuAFzaKSkM7zVZGhzyuTFh0VRJmlRRSZZTiOHLJJkSvJ4dDdewP3OY-rHItE52gLmtDZ-TvEo66Ddmtqz6c_wgpaxR5V30KjS3YJqQy3oHtj4e9437jRxCZS8BIOHchR1PbX5txl-fI-uEhvT5FaNVnYdxSTZsC-g8NtRk9ueFCdZrp6Pb_zukO3PI2KdtfMdFduGan9-DGF-91vw8Xg_Hc1BbtbCRgI20nNd1Dwu9oeesLppenDtqzZIT6UCNrzRnawmyiv2OJo19O9KrZbDZC-cVefz6h4JWDN--ZZqgsy3oy_mXLPeYD58-wK5dO5AF8Ozo8OfgU-pQNoekKtQjj2CquRBVxjbakLDJlMotGXcStLXhliqqQGX50ZaQwVmRaqcpyo0uJtqNJ04fQmdZT-xhYmclI4-9ZZWLsrZCpTqKkRAETx6kR3QDi9WrlxuOZU1qNs7xBYnYrnOMK526F8ziAt02b8xWax5XUr4gJctrq2LPR_sYCjo9As_J9kaQqJkD-AF62KE9XkOF_I9xpEeJeNu3qNaPkXpbM80suCeB5U00tKT5uausl0XQp4xAK7wAerdizmSCdWJG3NADRYtyGgBDG2zXT8cghjQt8f5U8DWBvzeKXw_r3__bk6lk8hZsJBQa5c6wd6CxmS_sMrpufi_F8tgtboj-gcihcKXf9nsan_tfBby_gT_Q
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3bbtMw9GgaCHjhfgkMMBJXsYg4TeMYCaFpMK3aViHUTXsLjuOsRWszmhZUPopv5BznMlLB3vaAIkVRfGzFzrna5wLw1HheqonSTKaVG_BMu0lX-m6YRSKSIZU49myxCdHvR4eH8tMK_KpjYcitsuaJllGnuaY98jd-gLIN0a0r3598c6lqFJ2u1iU0SrTYMYsfaLIV73of8P8-8_2tj4PNbbeqKuDqrpAzl3MjAykyL1Co7kRJKHVoUO_wAmOSINNJlkQhXirTkdBGhErKzARapRGqN5o2QJHlX0A-zsmFTHw-aE4tRGjLPVJWPTdAxb4K0rGheqRrBS4Zax7aEKHLW4JwWRz8IQ-XfTWXDmytHNy69r-t4HW4WmncbKMkkRuwYiY34dJe5VNwCxYHo0LnBq0IBGBDZcY5RVnhM9oVasHU_MgmLk0Z5bTIkXAKhpo-G6uveMfVmo9V2W06HSJ3Zi97A3LN2Xz1limGqkCaj0c_TbrOqrCAYxzKFku5DfvnMvE7sDrJJ-YesDSMPIXvw0xzHC2JOsr3_BTZJ-cdLboO8Bo7Yl1la6eiIcdxk2faYlSMGBVbjIq5A6-bPidlrpIzoV8Q0sXEyHBkrap4DPw-SgkWbwi_IzmVG3DgeQvyqEyI_jfAtRYgcirdbq4RM644ZRGfYqUDT5pm6knefxOTzwmmS_WUUDQ5cLckh2aCtB9HZ8EOiBahNACUP73dMhkNbR51gdZ5FHQcWK9J6vSz_r1u98-exWO4vD3Y2413e_2dB3DFJxcou2O3Bquz6dw8hIv6-2xUTB9Z3sHgy3mT2m9jKqkQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3bbtMw9Gjq0MQLd1hggJG4ikVL0iSOkRAa2yqqQVWhDe0tcxxnLVqb0QuofBpfxznOZaSCve0BRYqi-NiKnXO1zwXgqXacVBGl6UxJ23czZSeB8Owwi3gkQipx7JhiE7zXi46ORH8FflWxMORWWfFEw6jTXNEe-Zbno2xDdAvEVla6RfR3O-_OvtlUQYpOWqtyGgWK7OvFDzTfpm-7u_ivn3leZ-9g54NdVhiwVcDFzHZdLXzBM8eXqPpESShUqFEHcXytEz9TSZZEIV4yUxFXmodSiEz7SqYRqjqKNkOR_a9yVDKCFqy-3-v1P9dnGDw0xR8px57to5pfhuyYwD3SvHybTDcHLYrQdhticVk4_CEdlz03l45vjVTsXP-f1_MGXCt1cbZdEM9NWNHjW7D2qfQ2uA2LL8OpyjXaFwjABlKPcoq_wme0OOSCyfmJSWmaMsp2kSNJTRnaAGwkv-IdV24-kkW3yWSAfJu97B6Q087OqzdMMlQS0nw0_KnTTVYGDJziUKaMyh04vJSJ34XWOB_rdWBpGDkS34eZcnG0JGpLz_FSZKyu21Y8sMCtMCVWZR53KidyGtcZqA12xYhdscGu2LXgdd3nrMhiciH0C0LAmFgcjqxkGamB30fJwuJt7rWFS4UILHjegDwpUqX_DXCjAYg8TDWbKySNSx46jc8x1IIndTP1JL_Asc7nBBNQpSUUWhbcK0ijniDt1NEpsQW8QTQ1AGVWb7aMhwOTYZ2j3R75bQs2K_I6_6x_r9v9i2fxGNaQwuKP3d7-A7jqkW-U2crbgNZsMtcP4Yr6PhtOJ49KRsLg-LJp7Tcr87ME
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Viscoelastic+haemostatic+assay+augmented+protocols+for+major+trauma+haemorrhage+%3A+a+randomized%2C+controlled+trial&rft.jtitle=Intensive+care+medicine&rft.au=Baksaas-Aasen%2C+K&rft.au=Gall%2C+L.+S&rft.au=Stensballe%2C+J&rft.au=Juffermans%2C+N.+P&rft.date=2021-01-01&rft.pub=Springer&rft.issn=0342-4642&rft.volume=47&rft.issue=1&rft.spage=49&rft_id=info:doi/10.1007%2Fs00134-020-06266-1&rft.externalDocID=A723913788
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0342-4642&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0342-4642&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0342-4642&client=summon